Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT)

NCT01106534 is registered in ClinicalTrials.gov with Abbott Medical Devices as lead sponsor.

NCT NCT01106534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01106534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT)
Lead sponsor
Abbott Medical Devices
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2009
Completion date
July 31, 2015
Enrollment
870 (actual)
Sites
144

Conditions

As the registry lists them; a condition with its own page is linked.

chronic total occlusion of coronary artery, coronary artery disease, coronary artery stenosis, coronary disease, coronary restenosis, myocardial ischemia, vascular disease